source
- EyePoint's Phase 3 trial fails, prompting 53% staff cuts; Lilly signs China drug delivery partnershipEyePoint, a Watertown, Massachusetts biotech, reported that its experimental therapy did not meet primary endpoints in a Phase 3 study, marking a setback for the company. Following the trial failu…
- Veradermics reports Phase 3 minoxidil pill boosts hair coverage in menAfter a February IPO that raised more than $256 million and a strong share rally, Connecticut‑based Veradermics now has late‑stage data for its oral minoxidil candidate. In the Phase 3 Study 304,…